[
    {
        "molecule_name": "antibodies or antibody fragments or fusion proteins",
        "protein_target_name": "TNFR2",
        "binding_metric": "KD",
        "value": "<10^-6",
        "unit": "M",
        "raw_mentions": "In a preferred embodiment, when the bound KD has a value of less than 10 <sup>-6</sup> M、10 <sup>-7</sup> M、10 <sup>-8</sup> M、10 <sup>-9</sup> M or 10- <sup>10</sup> M, the binding molecules of the invention, particularly antibodies or antibody fragments or fusion proteins thereof, are said to specifically bind TNFR2. \nIn one embodiment, the KD values are measured using cells expressing TNFR2, such as HeLa transfectants expressing TNFR2, with KD values of less than 10 <sup>-6</sup> M. \nKD values are determined using Kums J, nelke J, B,V, siegmuld D, wajant H.MAbs.2017Apr;9 (3) determination by the method set forth in 506-520, with a KD value of less than 10 <sup>-6</sup> M. \nThus, in one embodiment, a fusion of the binding molecule with Gaussia princps luciferase as a reporter domain is used to measure the KD value of the binding molecule as described in Kums et al, with a KD value of less than 10 <sup>-6</sup> M."
    },
    {
        "molecule_name": "binding molecules",
        "protein_target_name": "TNFR2",
        "binding_metric": "K",
        "value": "100nM",
        "unit": "nM",
        "raw_mentions": "Here are the extracted sentences that meet the criteria:\n\nIn one embodiment, the binding molecules of the invention, particularly binding domains in antibodies, have an affinity for TNFR2 of about 400nM or less, 200nM or less, e.g., K of about 100nM, 50nM, 20nM, 10nM, 1nM, 500pM, 250pM, 200pM, 100pM or less.\nIn one embodiment, the affinity of the individual antigen binding sites of the binding molecules of the invention may be smallAt 1 μM, less than 750nM, less than 500nM, less than 250nM, less than 200nM, less than 150nM, less than 100nM, less than 75nM, less than 50nM, less than 10nM, less than 1nM, less than 0.1nM, less than 10pM, less than 1pM, or less than 0.1pM.\nIn some embodiments, kd is about 0.1pM to about 1 μm."
    },
    {
        "molecule_name": "binding molecules",
        "protein_target_name": "TNFR2",
        "binding_metric": "K",
        "value": "50nM",
        "unit": "nM",
        "raw_mentions": "Here are the extracted sentences that meet the criteria:\n\nIn one embodiment, the binding molecules of the invention, particularly binding domains in antibodies, have an affinity for TNFR2 of about 400nM or less, 200nM or less, e.g., K of about 100nM, 50nM, 20nM, 10nM, 1nM, 500pM, 250pM, 200pM, 100pM or less.\nIn one embodiment, the affinity of the individual antigen binding sites of the binding molecules of the invention may be smallAt 1 μM, less than 750nM, less than 500nM, less than 250nM, less than 200nM, less than 150nM, less than 100nM, less than 75nM, less than 50nM, less than 10nM, less than 1nM, less than 0.1nM, less than 10pM, less than 1pM, or less than 0.1pM.\nIn some embodiments, kd is about 0.1pM to about 1 μm."
    },
    {
        "molecule_name": "binding molecules",
        "protein_target_name": "TNFR2",
        "binding_metric": "K",
        "value": "20nM",
        "unit": "nM",
        "raw_mentions": "Here are the extracted sentences that meet the criteria:\n\nIn one embodiment, the binding molecules of the invention, particularly binding domains in antibodies, have an affinity for TNFR2 of about 400nM or less, 200nM or less, e.g., K of about 100nM, 50nM, 20nM, 10nM, 1nM, 500pM, 250pM, 200pM, 100pM or less.\nIn one embodiment, the affinity of the individual antigen binding sites of the binding molecules of the invention may be smallAt 1 μM, less than 750nM, less than 500nM, less than 250nM, less than 200nM, less than 150nM, less than 100nM, less than 75nM, less than 50nM, less than 10nM, less than 1nM, less than 0.1nM, less than 10pM, less than 1pM, or less than 0.1pM.\nIn some embodiments, kd is about 0.1pM to about 1 μm."
    },
    {
        "molecule_name": "binding molecules",
        "protein_target_name": "TNFR2",
        "binding_metric": "K",
        "value": "10nM",
        "unit": "nM",
        "raw_mentions": "Here are the extracted sentences that meet the criteria:\n\nIn one embodiment, the binding molecules of the invention, particularly binding domains in antibodies, have an affinity for TNFR2 of about 400nM or less, 200nM or less, e.g., K of about 100nM, 50nM, 20nM, 10nM, 1nM, 500pM, 250pM, 200pM, 100pM or less.\nIn one embodiment, the affinity of the individual antigen binding sites of the binding molecules of the invention may be smallAt 1 μM, less than 750nM, less than 500nM, less than 250nM, less than 200nM, less than 150nM, less than 100nM, less than 75nM, less than 50nM, less than 10nM, less than 1nM, less than 0.1nM, less than 10pM, less than 1pM, or less than 0.1pM.\nIn some embodiments, kd is about 0.1pM to about 1 μm."
    },
    {
        "molecule_name": "binding molecules",
        "protein_target_name": "TNFR2",
        "binding_metric": "K",
        "value": "1nM",
        "unit": "nM",
        "raw_mentions": "Here are the extracted sentences that meet the criteria:\n\nIn one embodiment, the binding molecules of the invention, particularly binding domains in antibodies, have an affinity for TNFR2 of about 400nM or less, 200nM or less, e.g., K of about 100nM, 50nM, 20nM, 10nM, 1nM, 500pM, 250pM, 200pM, 100pM or less.\nIn one embodiment, the affinity of the individual antigen binding sites of the binding molecules of the invention may be smallAt 1 μM, less than 750nM, less than 500nM, less than 250nM, less than 200nM, less than 150nM, less than 100nM, less than 75nM, less than 50nM, less than 10nM, less than 1nM, less than 0.1nM, less than 10pM, less than 1pM, or less than 0.1pM.\nIn some embodiments, kd is about 0.1pM to about 1 μm."
    },
    {
        "molecule_name": "binding molecules",
        "protein_target_name": "TNFR2",
        "binding_metric": "K",
        "value": "500pM",
        "unit": "pM",
        "raw_mentions": "Here are the extracted sentences that meet the criteria:\n\nIn one embodiment, the binding molecules of the invention, particularly binding domains in antibodies, have an affinity for TNFR2 of about 400nM or less, 200nM or less, e.g., K of about 100nM, 50nM, 20nM, 10nM, 1nM, 500pM, 250pM, 200pM, 100pM or less.\nIn one embodiment, the affinity of the individual antigen binding sites of the binding molecules of the invention may be smallAt 1 μM, less than 750nM, less than 500nM, less than 250nM, less than 200nM, less than 150nM, less than 100nM, less than 75nM, less than 50nM, less than 10nM, less than 1nM, less than 0.1nM, less than 10pM, less than 1pM, or less than 0.1pM.\nIn some embodiments, kd is about 0.1pM to about 1 μm."
    },
    {
        "molecule_name": "binding molecules",
        "protein_target_name": "TNFR2",
        "binding_metric": "K",
        "value": "250pM",
        "unit": "pM",
        "raw_mentions": "Here are the extracted sentences that meet the criteria:\n\nIn one embodiment, the binding molecules of the invention, particularly binding domains in antibodies, have an affinity for TNFR2 of about 400nM or less, 200nM or less, e.g., K of about 100nM, 50nM, 20nM, 10nM, 1nM, 500pM, 250pM, 200pM, 100pM or less.\nIn one embodiment, the affinity of the individual antigen binding sites of the binding molecules of the invention may be smallAt 1 μM, less than 750nM, less than 500nM, less than 250nM, less than 200nM, less than 150nM, less than 100nM, less than 75nM, less than 50nM, less than 10nM, less than 1nM, less than 0.1nM, less than 10pM, less than 1pM, or less than 0.1pM.\nIn some embodiments, kd is about 0.1pM to about 1 μm."
    },
    {
        "molecule_name": "binding molecules",
        "protein_target_name": "TNFR2",
        "binding_metric": "K",
        "value": "200pM",
        "unit": "pM",
        "raw_mentions": "Here are the extracted sentences that meet the criteria:\n\nIn one embodiment, the binding molecules of the invention, particularly binding domains in antibodies, have an affinity for TNFR2 of about 400nM or less, 200nM or less, e.g., K of about 100nM, 50nM, 20nM, 10nM, 1nM, 500pM, 250pM, 200pM, 100pM or less.\nIn one embodiment, the affinity of the individual antigen binding sites of the binding molecules of the invention may be smallAt 1 μM, less than 750nM, less than 500nM, less than 250nM, less than 200nM, less than 150nM, less than 100nM, less than 75nM, less than 50nM, less than 10nM, less than 1nM, less than 0.1nM, less than 10pM, less than 1pM, or less than 0.1pM.\nIn some embodiments, kd is about 0.1pM to about 1 μm."
    },
    {
        "molecule_name": "binding molecules",
        "protein_target_name": "TNFR2",
        "binding_metric": "K",
        "value": "100pM",
        "unit": "pM",
        "raw_mentions": "Here are the extracted sentences that meet the criteria:\n\nIn one embodiment, the binding molecules of the invention, particularly binding domains in antibodies, have an affinity for TNFR2 of about 400nM or less, 200nM or less, e.g., K of about 100nM, 50nM, 20nM, 10nM, 1nM, 500pM, 250pM, 200pM, 100pM or less.\nIn one embodiment, the affinity of the individual antigen binding sites of the binding molecules of the invention may be smallAt 1 μM, less than 750nM, less than 500nM, less than 250nM, less than 200nM, less than 150nM, less than 100nM, less than 75nM, less than 50nM, less than 10nM, less than 1nM, less than 0.1nM, less than 10pM, less than 1pM, or less than 0.1pM.\nIn some embodiments, kd is about 0.1pM to about 1 μm."
    }
]